SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association ...
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a peer-reviewed paper ...
Court expresses significant doubts about the validity of the patent asserted by 10x Genomics in its ongoing litigation with NanoString “We have maintained from the outset of this case that the patents ...
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic ...
Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...
A company with roots in developing tools for translational research has raised $15.3 million to execute the first step of its pursuit of market share in diagnostics. When it was granted the CE Mark in ...
10x Genomics has begun commercial shipments of a new 5,000–plex gene expression panel that increases plex by an order of magnitude over previous panels, a month after announcing the launch of the ...
NanoString, which has been acquired by Bruker, has won a victory in a patent battle with 10x Genomics. Billerica, MA-based Bruker said that the German Federal Patent Court has ruled in favor of ...
After it filed for bankruptcy early last month, the life science tool developer NanoString may have found a new home for its portfolio with the investment firm Patient Square Capital. Patient Square ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results